Cotsiranib, a TGF‐β1 and COX‐2 small interfering RNA inhibitor, is under investigation in basal cell carcinoma (NCT04669808) and in patients with advanced solid tumors with cholangiocarcinoma, hepatocellular carcinoma, or liver metastases (NCT04676633) [36, 37]. Here, TGFB1 is linked to basal cell carcinoma.